home / stock / ebs / ebs news


EBS News and Press, Emergent Biosolutions Inc. From 08/25/22

Stock Information

Company Name: Emergent Biosolutions Inc.
Stock Symbol: EBS
Market: NYSE
Website: emergentbiosolutions.com

Menu

EBS EBS Quote EBS Short EBS News EBS Articles EBS Message Board
Get EBS Alerts

News, Short Squeeze, Breakout and More Instantly...

EBS - Monkeypox response from feds topic of Senate hearing next month - Bloomberg

Biden administration health officials will testify before the Senate Health, Education, Labor and Pensions Committee at a hearing in mid-September, Bloomberg reported. On August 23, Sen. Patty Murray (D-Wash.), chairwoman of the committee, sent a letter to Dawn O'Conne...

EBS - Emergent BioSolutions reaches 52-week low; down 43% YTD

Emergent BioSolutions ( NYSE: EBS ) reached a new 52-week low of $26.79. Year to date, shares are down ~43% . In its Q2 financial results earlier in August, the company missed on the top and bottom line s. On August 10, Emergent ( EBS ) received a warni...

EBS - Emergent BioSolutions Inc. 2022 Q2 - Results - Earnings Call Presentation

The following slide deck was published by Emergent BioSolutions Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Emergent BioSolutions Inc. 2022 Q2 - Results - Earnings Call Presentation

EBS - 3 Top Monkeypox Stocks to Buy Right Now

InvestorPlace - Stock Market News, Stock Advice & Trading Tips With the latest outbreak now reported in all 50 states per ABC News , investors may want to consider the top monkeypox stocks to buy right now. From an investment perspective, this latest health threat poses powerful cat...

EBS - Emergent BioSolutions: Now Long Through Sale Of October Put Spreads

Summary Emergent BioSolutions lost close to $20 a share or 40%+ since the turn of the year. EBS stock is now coming up against long-term support. We believe support will hold due to rising profitability and a very keen valuation. We may add more capital to our longs when w...

EBS - Chimerix: A Confusing Business Strategy Makes It Unconvincing

Chimerix has been a developer of antivirals. Its key antiviral drug, tembexa, got approved last year and is being sold to a third party. The company's pivot to oncology leaves us confused. I covered Chimerix, Inc. ( CMRX ) last year , when it had just transitione...

EBS - Emergent ticks lower after FDA warning on Baltimore facility

The shares of contract manufacturer Emergent BioSolutions ( NYSE: EBS ) turned lower on Monday morning after the company disclosed that the FDA issued a warning related to its Camden manufacturing facility in Baltimore, Maryland. According to the company, the letter receiv...

EBS - Additional 135M COVID-19 vaccine doses destroyed at Emergent BioSolutions Baltimore plant

The House Committee on Oversight and Reform has found evidence that an additional 135M COVID-19 vaccine doses from a troubled Emergent BioSolutions ( NYSE: EBS ) were trashed. This brings the total number of destroyed doses to more than 525M. A committee news relea...

EBS - U.S. monkeypox cases exceed 10,000

According to the latest data compiled by the Centers for Disease Control and Prevention (CDC), the recent monkeypox outbreak has led to 10,392 cases as of Wednesday. The country has added 900 cases on Wednesday alone per the Our World in Data project, a public online data hub base...

EBS - U.S. declares monkeypox a public health emergency

The Biden administration declared the current monkeypox outbreak a public health emergency on Thursday in a bid to marshal resources and raise awareness to contain the fast-spreading virus. Previously, The Washington Post reported the government plans, citing two officials. “...

Previous 10 Next 10